The autoimmune blistering disease represents a group of classic autoantibody-mediated diseases. While corticosteroids and immunosuppression represent the mainstay of therapy, we still need novel therapies that offer promise towards more targeted, efficient, and safer therapies. As an industry-leading biopharmaceutical company, Creative Biolabs has extensive experience in cell-based therapy and therapeutic antibody development for autoimmune skin diseases. With rich experience accumulated from practice, we are confident in offering reliable treatment development services to global customers.
Autoimmune blistering diseases (AIBD) comprise a diverse group of disorders that are unified by a loss of tolerance to and subsequent autoantibody generation against structural components of the skin and mucous membrane. On a structural level, AIBDs universally result in destabilization of cell-cell or cell-matrix adhesion and subsequent acantholysis or subepidermal blistering. Following the loss of tolerance and induction of autoantibody production, the pathogenesis of the two major subtypes of AIBD, pemphigus, and pemphigoid, differs substantially.
The pemphigus subgroup is characterized by the formation of autoantibodies against desmoglein cadherin molecules. Pemphigus vulgaris (PV) is the most common form and is most commonly associated with autoantibodies against desmoglein 1 and 3, while pemphigus foliaceous (PF) is associated with loss of tolerance against desmoglein 1. Exposure to anti-desmoglein antibodies induces signal transduction pathways leading to keratinocyte retraction and loss of adhesion from surrounding cells. Subsequent apoptosis leads to the formation of flaccid blisters and erosions on the skin and mucous membranes. Autoantibodies to several other keratinocyte proteins can additionally lead to subsequent acantholysis. Pemphigoid diseases are comprised of several conditions including bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA). Targeting of distinct antigens results in the immune complex (IC)- mediated complement activation, granulocyte recruitment, and subsequent protease and reactive oxygen species (ROS) mediated basement membrane zone (BMZ) destruction.
Fig.1 A diagram of the targets for autoantibodies in autoimmune bullous skin diseases. (Saschenbrecker, 2019)
Focusing on the treatment strategy development of autoimmune skin diseases for more than 10 years, Creative Biolabs has accumulated irreplaceable experience and comprehensive resources such as advanced facilities, the latest technologies, and professional experts. With all these precious conditions established step by step during practice, we are confident in providing high-quality services including but not limited to:
Creative Biolabs is eager to promote the development of therapeutic strategies for autoimmune skin diseases through our reliable services. If you are interested in cell-based therapy or therapeutic antibody development services, please feel free to contact us for more information.
Reference
For Research Use Only | Not For Clinical Use
Contact us
USA
Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.
Copyright © 2024 Creative Biolabs. All Rights Reserved.
